Patents by Inventor Jonathan Lorne BRAMSON

Jonathan Lorne BRAMSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T cell-antigen coupler with various construct optimizations
    Patent number: 11976117
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 7, 2024
    Assignee: McMaster University
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • T cell-antigen coupler with various construct optimizations
    Patent number: 11878035
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: January 23, 2024
    Assignees: Triumvira Immunologics USA, Inc., McMaster University
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • CELLS COMPRISING T CELL-ANTIGEN COUPLERS AND USES THEREOF
    Publication number: 20240016841
    Abstract: ?? T cells comprising a molecule comprising (i) a target-specific antigen-binding domain, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.
    Type: Application
    Filed: November 5, 2021
    Publication date: January 18, 2024
    Inventors: Jonathan Lorne Bramson, SeungMi Yoo, Sarah Asbury, Allyson Moore, Ling Wang, Brian Philip
  • T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
    Publication number: 20230210905
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 6, 2023
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
    Publication number: 20220331364
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Application
    Filed: June 30, 2022
    Publication date: October 20, 2022
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • BCMA T cell-antigen couplers and uses thereof
    Patent number: 11453723
    Abstract: BCMA T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds BCMA, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: September 27, 2022
    Assignee: McMaster University
    Inventors: Jonathan Lorne Bramson, Joanne Alicia Hammill, Christopher W. Helsen
  • T cell-antigen coupler with various construct optimizations
    Patent number: 11406667
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: August 9, 2022
    Assignees: Triumvira Immunologies USA, Inc., McMaster University
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
    Publication number: 20210369780
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Application
    Filed: August 4, 2021
    Publication date: December 2, 2021
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • T cell-antigen coupler with various construct optimizations
    Patent number: 11110123
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: September 7, 2021
    Assignees: Triumvira Immunologics USA, Inc., McMaster University
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • T cell-antigen coupler with various construct optimizations
    Patent number: 11111298
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: September 7, 2021
    Assignee: McMaster University
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
    Publication number: 20200308278
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Jonathan Lorne BRAMSON, Christopher W. HELSEN, Joanne Alicia HAMMILL, Kenneth Anthony MWAWASI
  • T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
    Publication number: 20200261500
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Jonathan Lorne BRAMSON, Christopher W. HELSEN, Joanne Alicia HAMMILL, Kenneth Anthony MWAWASI
  • T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
    Publication number: 20200239571
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Application
    Filed: March 20, 2020
    Publication date: July 30, 2020
    Inventors: Jonathan Lorne BRAMSON, Christopher W. HELSEN, Joanne Alicia HAMMILL, Kenneth Anthony MWAWASI
  • T cell-antigen coupler with various construct optimizations
    Patent number: 10640562
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: May 5, 2020
    Assignee: MCMASTER UNIVERSITY
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
    Publication number: 20200024345
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Application
    Filed: June 14, 2019
    Publication date: January 23, 2020
    Inventors: Jonathan Lorne BRAMSON, Christopher W. HELSEN, Joanne Alicia HAMMILL, Kenneth Anthony MWAWASI